Revolutionary Urine Test for Early Lung Cancer Detection
Scientists at the University of Cambridge have developed an innovative urine test that promises to revolutionize lung cancer diagnosis, enabling detection at an exceptionally early stage. Currently tested only on mice and undergoing clinical validation, this novel test employs a groundbreaking technology: an injectable sensor capable of identifying specific proteins in urine that promote cancer cell development, in this case, in the lungs.
These proteins are emitted by so-called ‘zombie’ or ‘senescent’ cells. When these damaged cells accumulate in the body instead of being eliminated naturally, they release distinctive proteins that reprogram their surrounding environment, leading to uncontrolled cell multiplication typical of neoplasia. The presence of these proteins can thus be detected in urine.
"We hope to start testing this analysis in humans within the next year," said Ljiljana Fruk, a Cambridge researcher and co-author of the study. "We know that before tumors appear, there are changes in the tissues that will be affected by cancer, and one of these is the accumulation of damaged cells that are not eliminated organically but instead reprogram the tissues to favor neoplastic development."
This breakthrough could significantly improve lung cancer diagnosis and treatment outcomes, as early detection is crucial for effective intervention. Keep an eye on this space for further developments in this promising area of medical research.
